Skip to main content

Alentis raises 12.5 million Swiss francs

Thomas Baumert, Alentis
| News

Alentis raises 12.5 million Swiss francs

30.04.2019

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by BPI France, Schröder Adveq and the HTGF. Alentis develops therapeutics in advanced liver disease and cancer.

Thomas Baumert, Alentis

BaseLaunch, a healthcare accelerator operated by BaselArea.swiss, has been instrumental as an early stage financial and operational supporter in the formation of the company. Very important has also been SATT Conectus – the tech transfer office of all the players in public research in Alsace – by providing building and securing the IP portfolio.

According to a press release, Alentis was founded upon research work conducted by the group of Professor Thomas Baumert, the principal founder of the company. He works at the University of Strasbourg, the Inserm Institute for Viral and Liver Disease, the Laboratory of Excellence HepSYS and the Institut Hospitalo-Universitaire Strasbourg.

Alentis’ lead program is a humanized monoclonal antibody against a target that is fundamental to the pathology of liver fibrosis and hepatocellular carcinoma (HCC). Alentis’ research is powered by its proprietary drug discovery platform, which is based on a prognostic liver disease signature holding promise for further drug candidates in liver disease.

Andreas Wallnöfer, General Partner at BioMedPartners and board member of Alentis, describes Baumert’s research as “truly translational, with the result that a rapid transition from preclinical research to clinical development can be expected.

Alentis is led by Dr. Markus Ewert, who was previously CBO at Ablynx, headed global corporate development at GE Healthcare, and held various leadership positions at Novartis.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.